Cortecs Flu Vaccine Enters Phase I

9 December 1996

- As was reported in the Marketletter, November 25, Cortecs has now officially announced the start of its Phase I trial with Flustat, its oral influenza vaccine. It will include 40 healthy subjects who will be divided into four groups to determine the preferred vaccinating regime. The systemic and mucosal immune responses will also be tested. It is hoped that an oral vaccine will have fewer side effects and will induce compliance compared to the injectable formulation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight